- Nachrichtendetail
-
20.06.2024 14:55:03 - dpa-AFX: *GILEAD'S LENACAPAVIR SHOWS 100% EFFICACY IN HIV PREVENTION FOR CISGENDER WOMEN IN PHASE 3 TRIAL
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
Gilead Sciences | 885823 | NASDAQ | 70,890 | 15.07.24 21:07:32 | +0,930 | +1,33% | 70,880 | 70,890 | 70,400 | 69,960 |
